carvedilol has been researched along with neuropeptide y in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Böhm, M; Ettelbrück, S; Flesch, M; Knorr, A; Maack, C; Paul, M; Pinto, YM; Teisman, AC; van Gilst, WH; Zolk, O | 1 |
| Hasan, W; Khan, F; Mudd, JO; Thornburg, KL; Toyooka, A; Tyrrell, C | 1 |
2 other study(ies) available for carvedilol and neuropeptide y
| Article | Year |
|---|---|
Beta-adrenergic signal transduction following carvedilol treatment in hypertensive cardiac hypertrophy.
Topics: Adenylate Cyclase Toxin; Adenylyl Cyclases; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Animals, Genetically Modified; Binding, Competitive; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Colforsin; Down-Regulation; GTP-Binding Protein alpha Subunits, Gi-Go; Guanylyl Imidodiphosphate; Heart Rate; Isoproterenol; Male; Neuropeptide Y; Pertussis Toxin; Propanolamines; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, beta; Signal Transduction; Virulence Factors, Bordetella | 1998 |
The neuropeptide galanin promotes an anti-thrombotic phenotype on endocardial endothelial cells from heart failure patients.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Adult; Aged; Antithrombins; Carbazoles; Carvedilol; Cells, Cultured; Endothelial Cells; Galanin; Heart Failure; Heart Ventricles; Humans; Isoproterenol; Male; Middle Aged; Neuropeptide Y; Phenotype; Propanolamines; Propranolol; Protein Multimerization; Thrombin | 2017 |